Priveterra Acquisition Corp. (NASDAQ:PMGM) and its biopharmaceutical target, AEON Biopharma, announced this morning that they have secured an additional $20 million in commitments from existing investors in connection to its business combination.
The SPAC brought about $276 million into the deal through its current trust but aside from today’s funding, it has not yet supplemented this with other committed sources of capital. Priveterra must maintain at least $45 million in cash available in order for the deal to close, which means the SPAC potentially still needs to secure an additional $25 million in capital.
Under the terms of the commitments, the issued security is to be exchanged or converted into Class A common stock of the combined company once the proposed merger is completed, and is expected to fund concurrently with or immediately prior to the closing of the deal.
PMGM announced its $201.8 million business combination with drug developer AEON on December 13, 2022. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.
AEON Biopharma also announced in December the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of episodic migraine. The company expects to announce top-line data from the study in the second half of 2023.
Best SPAC I Acquisition Corp. (NASDAQ:BSAAU) announced the pricing of its $55 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “BSAAU”, Friday, June 13, 2025. The new SPAC plans to combine with a consumer goods company with a total enterprise value between $100 million and $600 million....
Blue Acquisition Corp. (NASDAQ:BACCU) announced the pricing of its $175 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “BACCU”, Friday, June 13, 2025. The new SPAC intends to combine with a target company within a manufacturing company or data center that aligns with green energy initiatives and...
1RT (NASDAQ:ONCHU) has filed for a $150 million SPAC with confident terms in a market that has been recently much more welcoming to SPAC issuance. The new SPAC is including 1/4 warrants in its units, which is the slimmest warrant coverage offered by a newly-filed SPAC since Cohen Circle II (NASDAQ:CCIIU) put out its own...
At the SPAC of Dawn This week, the market has taken on better-than-expected inflation news and SPACs continue to see old friends leaning toward listing in the traditional way. This time it is crypto exchange Bullish which is reportedly seeking an IPO three years after canceling its combination with a SPAC. Bullish was initially engaged...
EQV Ventures II (NYSE:EVACU) has filed for a $350 million SPAC aiming to give its team a second vehicle to pursue targets within hopefully a more receptive market environment than its first. The team’s first SPAC, EQV I (NYSE:EQV), broke price on its debut on August 7, 2024, finishing with a one-day VWAP of $9.9452...